Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | ANPEP | P15144 | 4/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19964285 | 1.00 | MMP2 (0.35) | MMP2ANPEPBRD4CYP3A4MAPT | |
| SCHEMBL4146529 | 1.00 | MMP2 (0.35) | MMP2ANPEPBRD4CYP3A4MAPT | |
| SCHEMBL22360759 | 0.85 | PPM1D (0.34) | PPM1D | |
| SCHEMBL29303856 | 0.85 | PPM1D (0.34) | PPM1D | |
| SCHEMBL4151736 | 0.85 | PPM1D (0.34) | PPM1D | |
| SCHEMBL3429014 | 0.84 | SMN1; SMN2 (0.36) | MMP2ANPEPSMN1; SMN2PPM1D | |
| SCHEMBL30591269 | 0.84 | SMN1; SMN2 (0.36) | MMP2ANPEPSMN1; SMN2PPM1D | |
| SCHEMBL15745590 | 0.83 | — | — | |
| SCHEMBL4139942 | 0.83 | MMP2 (0.52) | MMP2ANPEPALDH1A1 | |
| SCHEMBL15130169 | 0.83 | MMP2 (0.39) | MMP2ANPEPSMN1; SMN2PPM1DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394970-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7674915-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2010-03-09 | — | — | US | disclosed |
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | AJINOMOTO CO. INC (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | PTMA, GRIK5, GLUL | MMP2 997/4885ANPEP 281/4885BRD4 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.